Can a dietary intervention known for reducing cardiovascular risk factors prevent cognitive decline in healthy older individuals? A team of researchers explored this question in a recent study.
The FDA has examined the results of a recent confirmatory trial to verify the clinical benefit of an amyloid beta-directed antibody for the treatment of Alzheimer disease.
Researchers investigated the association and the potential sex differences between hypertension and blood pressure in early adulthood (ages 30-40 years) with late-life brain health.
Following two 12-week studies, the FDA has approved the first ever medication for treating agitation in patients with dementia due to Alzheimer disease.
To better understand the relationship between nutritional status and cognitive decline, the researchers examined the impact of vitamin D levels on the risk of Alzheimer disease and dementia in older adults....
Researchers performed a systematic review and meta-analyses to better understand the relationship between antihypertensive agent use and the risk of Alzheimer disease development.